The following is a summary of updated recommendations and new data on COVID-19 vaccination in MS patients. (See also DMTs and vaccine response in MS: the evidence to date, NeuroSens, July 27, 2021.) Read More
Neurology
High-efficacy DMTs – Early treatment and novel endpoints
November 22, 2021ECTRIMS SPECIAL REPORT
The recently concluded European Committee on Treatment and Research in MS (ECTRIMS) annual meeting presented a number of new approaches for evaluating the efficacy of high-efficacy disease-modifying therapies. Read More
ECTRIMS special report: Update on anti-CD20 agents
November 9, 2021The European Committee for Treatment and Research in MS (ECTRIMS) annual meeting presented new data that helped to clarify the mode of action of anti-CD20 agents and address some safety issues that have arisen during the COVID-19 pandemic. Read More
ECTRIMS 2021 SLIDE DECK
October 22, 2021Selected highlights from ECTRIMS 2021
Virtual Congress – 13-15 October 2021
52 slides
Scientific review:
Dr. Daniel Selchen, Senior Consultant, BARLO MS centre, St. Michael’s Hospital, Toronto, Canada
Read More
How prognostic is NEDA?
October 20, 2021A new study has found that a high proportion of MS patients with no evidence of disease activity (NEDA) in the first two years of treatment will experience relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) (Prosperini et al. Neurol Neuroimmunol Neuroinflamm 2021;8:e1059). Read More